Use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate for treating portal gastropathies in patients with liver cirrhosis

摘要

The invention relates to medicine, particularly to hepatology.According to the invention, the use of 3-(2,2,2-trimethylhydrazinium)propionate dihydrate is claimed for treating portal gastropathies in patients with liver cirrhosis, intravenously, 500 mg, 1…2 times a day, for 7…10 days, then per os, 500 mg, 1…2 times a day, for 4…6 weeks.